Alpine Immune Sciences Inc (ALPN) Gets a Buy Rating from Oppenheimer


Oppenheimer analyst Mark Breidenbach reiterated a Buy rating on Alpine Immune Sciences Inc (NASDAQ: ALPN) yesterday and set a price target of $13. The company’s shares closed yesterday at $6.85, close to its 52-week low of $6.77.

Breidenbach wrote:

“Thursday, Alpine reported a 2Q net loss of $(0.57) per share, higher than our estimate of $(0.41). The company is preparing to file an IND for ALPN-101, a dual immune checkpoint modulator targeting both CD28 and ICOS that is based on the company’s variant immunoglobulin domain (vIgD) platform. We believe vIgD-based therapeutics, derived from the natural binding partners of immune checkpoints, could provide a versatile alternative to conventional bispecific antibodies with applications in oncology and autoimmune disease. The company remains on track to initiate a Phase 1 trial of a second vIgD-based product, ALNP-202, could enter the clinic in 2H19. With a cash runway projected to last until 1H20, we reiterate our Outperform rating and $13 PT.”

According to TipRanks.com, Breidenbach is a 4-star analyst with an average return of 9.7% and a 43.0% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Global Blood Therapeutics, and Sorrento Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alpine Immune Sciences Inc with a $13 average price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts